Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ F-1 Registration statement for certain foreign private issuers Accession Number: 0001178913-23-000920 Act: 33 Size: 645 KB 网页链接
$Sol-gel(SLGL)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001178913-23-000918 Act: 33 Size: 129 KB 网页链接
$Sol-gel(SLGL)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-23-000913 Act: 34 Size: 8 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-000811 Act: 34 Size: 345 KB 网页链接
$Sol-gel(SLGL)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-000686 Act: 34 Size: 134 KB 网页链接
$Sol-gel(SLGL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-23-000589 Act: 34 Size: 91 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-000531 Act: 34 Size: 137 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-000346 Act: 34 Size: 3 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-000332 Act: 34 Size: 390 KB 网页链接
$Sol-gel(SLGL)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001178913-23-000308 Act: 33 Size: 752 KB 网页链接